Abstract 895P
Background
Bev has obtained European (EU) approval for EOC pts treated in fl on 12/2011. This study addresses the question of how Bev is used in routine practice for the fl treatment of OC pts.
Methods
102 centers were selected to be representative of the distribution of OC pts in France. All consecutive OC pts treated in fl in each center were screened in order to include at least 500 pts who gave their consent to participate to the ENCOURAGE cohort evaluating the long term Bev use in routine practice. We report here how Bev was prescribed in this series of pts.
Results
From 04/2013 to 02/2015, 1158 evaluable pts representing 15% of French incidence cases were screened in academic hospital (15%), cancer center (29%), general hospital (25%), private center (31%). Bev was administered in 557 (48%) pts and mostly according to the label: with carboplatin (99%) and paclitaxel (98%), for stage IIIB-IV (97%), and at a dose of 15mg/kg (80.2%). Bev was NOT prescribed in 601/1158 pts and reasons were specified for 487pts. These were comorbidity including age over 70 (29%), neo-adjuvant strategy (22%), early stage (20%), inclusion in a trial (13%), no macroscopic residue after initial surgery (11%), early disease progression or death (3%), patient refusal (2%). Interestingly, in this series of 1158 consecutive pts, only about 1/3 of pts with comorbidity/age over 70, or no residue after initial surgery or treated with a neo-adjuvant strategy were excluded from Bev treatment, reflecting the heterogeneity of practice among centers.
Conclusions
Bev was administered in 1st line EOC treatment according to the EU label for the great majority of pts . However, the large variability of Bev prescription when patients had comorbidity, age over 70 or were treated with a neo-adjuvant strategy reflects the need of OC trials focusing on these populations of patients.
Clinical trial identification
NCT01832415
Legal entity responsible for the study
ARCAGY-GINECO
Funding
Roche
Disclosure
J-L. Mouysset: Roche, Astellas, Sanofi, Janssen, Hospira, Novartis, Sandoz, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract